View Future GrowthReboost Blockchain 과거 순이익 실적과거 기준 점검 3/6지난 몇 년간 Reboost Blockchain 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률16.27%매출 성장률1,535,100.00%자기자본이익률n/a순이익률137.36%최근 순이익 업데이트31 Dec 2024최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Jean-Charles Dudek was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 07Reboost Blockchain Corp., Annual General Meeting, Jun 10, 2026Reboost Blockchain Corp., Annual General Meeting, Jun 10, 2026. Location: 3 rue d heliopolis, paris France공시 • Feb 17Pyratzlabs signed a letter of intent to acquire Reboost Blockchain Corp. (ENXTPA:MLCOT) in a reverse merger transaction.Pyratzlabs signed a letter of intent to acquire Reboost Blockchain Corp. (ENXTPA:MLCOT) in a reverse merger transaction on February 15, 2026. The transaction is subject to both shareholder approval and regulatory clearance before it can be finalized. The transaction is expected to close in the first half of 2026.New Risk • Nov 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-€21k). Revenue is less than US$1m (€15k revenue, or US$18k). Market cap is less than US$10m (€2.00m market cap, or US$2.31m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (29% average weekly change). Negative equity (-€82k). Revenue has declined by 100% over the past year. Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€268.1k market cap, or US$289.6k).New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 100% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-€82k). Revenue has declined by 100% over the past year. Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€67.0k market cap, or US$74.0k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€82k). Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€268.1k market cap, or US$295.3k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).공시 • Jul 12Gour Medical SA announced that it has received €0.135 million in fundingGour Medical SA announced a private placement of 3,375,000 shares at a price of €0.04 per share for gross proceeds of €135,000 on July 10, 2023.New Risk • Jul 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 303% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€82k). Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€536.3k market cap, or US$588.0k).Board Change • Jun 19No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 25No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Nov 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Oct 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jul 07No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 12No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역Reboost Blockchain가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이ENXTPA:MLCOT 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 24000031 Dec 23000031 Dec 22000031 Dec 21000031 Dec 20000031 Dec 19000031 Dec 18000031 Dec 17000031 Dec 160000양질의 수익: MLCOT는 고품질 수익을 보유하고 있습니다.이익 마진 증가: MLCOT는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: MLCOT는 지난 5년 동안 흑자전환했습니다.성장 가속화: MLCOT는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: MLCOT는 지난해 흑자전환하여 지난 해 수익 성장률을 Pharmaceuticals 업계(3.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: MLCOT의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/09 11:05종가2026/06/09 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Reboost Blockchain Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Board Change • May 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Jean-Charles Dudek was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 07Reboost Blockchain Corp., Annual General Meeting, Jun 10, 2026Reboost Blockchain Corp., Annual General Meeting, Jun 10, 2026. Location: 3 rue d heliopolis, paris France
공시 • Feb 17Pyratzlabs signed a letter of intent to acquire Reboost Blockchain Corp. (ENXTPA:MLCOT) in a reverse merger transaction.Pyratzlabs signed a letter of intent to acquire Reboost Blockchain Corp. (ENXTPA:MLCOT) in a reverse merger transaction on February 15, 2026. The transaction is subject to both shareholder approval and regulatory clearance before it can be finalized. The transaction is expected to close in the first half of 2026.
New Risk • Nov 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-€21k). Revenue is less than US$1m (€15k revenue, or US$18k). Market cap is less than US$10m (€2.00m market cap, or US$2.31m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).
New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (29% average weekly change). Negative equity (-€82k). Revenue has declined by 100% over the past year. Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€268.1k market cap, or US$289.6k).
New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 100% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-€82k). Revenue has declined by 100% over the past year. Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€67.0k market cap, or US$74.0k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€82k). Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€268.1k market cap, or US$295.3k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
공시 • Jul 12Gour Medical SA announced that it has received €0.135 million in fundingGour Medical SA announced a private placement of 3,375,000 shares at a price of €0.04 per share for gross proceeds of €135,000 on July 10, 2023.
New Risk • Jul 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 303% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€82k). Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€536.3k market cap, or US$588.0k).
Board Change • Jun 19No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 25No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Nov 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Oct 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jul 07No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 12No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.